Sign in

NCT07173972RecruitingPhase 2

Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.

PROSARC-2. Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. A Single-arm, Multicenter, Phase II Clinical Trial.

Source: ClinicalTrials.gov · Last updated 28 Jan 2026

Brief summary (registry, in English)

The purpose of the study is to study if dose escalated proton radiotherapy can improve local controll for patients with inoperable soft tissue sarcomas. The standard treatment is photon-based radiation. By using proton radiotherapy instead, the hypothesis is that the dose can be increased to enhance treatment effectiveness without increasing side effects. The planned radiation dose is 56 Gy in 16 fractions (treatments) over 4 weeks (4 fractions per week), with a maximum dose escalation centrally in the tumor up to 80 Gy (5 Gy per fraction). At the same time, the study will investigate biomarkers that can predict treatment response, including changes in the tumor's genetic material (DNA), measurements of various molecules in the bloodstream, and the tumor's appearance on MRI scans. The primary endpoint is local control after 2 years, meaning that the treated tumor has not grown during this period. Secondary endpoints include overall survival, progression-free survival, radiological response rates, side effects, and quality of life. The study will be conducted in Norway, with a planned inclusion of 40 patients.

Status (registry)
Recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
40 (estimated)
First submitted
8 Sept 2025
Start date
26 Jan 2026
Primary completion date
26 Jan 2029
Lead sponsor
Oslo University Hospital
Diseases
Sarcoma
NCT number
NCT07173972

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 40
  • From 26 Jan 2026 to the primary completion date, 26 Jan 2029
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients with a prior or concurrent malignant disease whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of this clinical trial are not eligible. Patients with a history of breast cancer, requiring continued hormonal treatment (e.g. anti-estrogen or an aromatase inhibitor) may be included. Patients with a history of prostate cancer, requiring continued support with luteinizing hormone releasing hormone (LHRH) agonists, with or without androgens, may be included.
  • Previous radiotherapy to the tumor site.
  • Administration of systemic cancer therapy (i.e. chemotherapy, targeted therapy or immune therapy) within 14 days prior to the first fraction of radiotherapy.

Other

  • Patients with pacemakers and/or implanted defibrillators.
  • Patients not able to give an informed consent or comply with study regulations as deemed by study investigator.

Who the study is looking for

  • ≥ 18 years of age at the time of informed consent.
  • Histological diagnosis of soft tissue sarcoma including gastrointestinal stromal tumor (GIST).
  • Measurable disease according to RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
  • For patients with metastatic disease a life-expectancy greater than 2 years should be expected.
  • Before patient registration, written informed consent must be given according to national and local regulations.
  • Ability to fill in patient questionnaires and comply with study procedures, including travelling to Bergen or Oslo for Proton Beam radiotherapy.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Haukeland University Hospital
Coordinator of this site? Confirm its status
BergenNorwayNot yet recruiting
Oslo University Hospital
Coordinator of this site? Confirm its status
OsloNorwayRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.